GADL1: Potential Drug Target for Psychiatric Disorders (G339896)

Target Name: GADL1

NCBI ID: G339896

GADL1

GADL1: Potential Drug Target for Psychiatric Disorders

GADL1 (HuADC), a gene located on chromosome 17, has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders. The HuADC gene encodes a protein known as the brain-derived neurotrophic factor (BDNF), a protein that is known to play a crucial role in the development and maintenance of neural circuits in the brain.

Research has shown that individuals with certain psychiatric and neurological disorders, such as depression, anxiety, and Alzheimer's disease, have lower levels of BDNF in their brains. Additionally, individuals with certain genetic variants, such as the single nucleotide polymorphism (SNP) rs1090528, have been shown to have lower levels of BDNF.

GADL1 has also been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Studies have shown that individuals with certain genetic variants, such as the SNP rs1090528, have an increased risk of developing these disorders and also have lower levels of BDNF in their brains.

The potential drug target for GADL1 is the use of neurotrophic factors, such as BDNF, to treat psychiatric and neurological disorders. Neurotrophic factors are a type of protein that is known to promote the growth and survival of neural cells and the formation of new neural connections.

One of the main drugs that is being targeted by GADL1 is a neurotrophic factor receptor antagonist, such as donanemab. Donanemab is a drug that is used to treat Alzheimer's disease and other neurological disorders. Studies have shown that donanemab is able to increase the levels of BDNF in the brains of individuals with Alzheimer's disease and also has been shown to improve cognitive function in individuals with these disorders.

Another drug that is being targeted by GADL1 is a BDNF gene knockdown drug, such as tamperdone. Tamperdone is a drug that is used to treat Alzheimer's disease and other neurological disorders. Studies have shown that tamperdone is able to decrease the levels of BDNF in the brains of individuals with Alzheimer's disease and also has been shown to improve cognitive function in individuals with these disorders.

In conclusion, GADL1 (HuADC) is a gene that has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders. The HuADC gene encodes a protein known as BDNF, which is known to play a crucial role in the development and maintenance of neural circuits in the brain. Studies have shown that individuals with certain psychiatric and neurological disorders, as well as individuals with certain genetic variants, have lower levels of BDNF in their brains. Additionally, GADL1 has also been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The potential drug targets for GADL1 include neurotrophic factors, such as BDNF, and BDNF gene knockdown drugs, such as tamperdone.

Protein Name: Glutamate Decarboxylase Like 1

Functions: May catalyze the decarboxylation of L-aspartate, 3-sulfino-L-alanine (cysteine sulfinic acid), and L-cysteate to beta-alanine, hypotaurine and taurine, respectively. Does not exhibit any decarboxylation activity toward glutamate

The "GADL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GADL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets